Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Income from Continuing Operations came in at 19847000.0 in Q1 2026, down 16.64% year-on-year from 23809962.98 in Q1 2025, and down 27.58% on a QoQ basis from 15556000.0 in Q4 2025.
Jushi Holdings (JUSHF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Income from Continuing Operations data on file, last reported at 19847000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 16.64% year-over-year to 19847000.0 in Q1 2026; TTM through Mar 2026 was 71423000.0, a 50.56% decrease from a year earlier, with the FY2025 full-year figure at 68591000.0, down 40.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19847000.0, down from 15556000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for JUSHF reached as high as 12066000.0 in Q2 2022 and fell as low as 139937000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 23802411.76 across 5 years, with a median of 17015000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 357.74% in 2022 and fell as far as 2353.05% in 2022.
- Year by year, Income from Continuing Operations stood at 139937000.0 in 2022, then surged by 87.13% to 18004000.0 in 2023, then surged by 30.75% to 12468000.0 in 2024, then retreated by 24.77% to 15556000.0 in 2025, then fell by 27.58% to 19847000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 19847000.0 in Q1 2026, 15556000.0 in Q4 2025, and 23689000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | -19.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.85 Mn |
| Dec 31, 2025 | -15.56 Mn |
| Sep 30, 2025 | -23.69 Mn |
| Jun 30, 2025 | -12.33 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -12.47 Mn |
| Sep 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -18.36 Mn |
| Dec 31, 2023 | -18.00 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -14.04 Mn |
| Mar 31, 2023 | -12.44 Mn |
| Dec 31, 2022 | -139.94 Mn |
| Sep 30, 2022 | -54.70 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | -19.76 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 39.68 Mn |
| Jun 30, 2021 | 2.64 Mn |